Leukemia Society to Launch Global Pediatric Trial Collaboration
The Leukemia and Lymphoma Society is partnering with PRA Health Sciences to launch the first global master clinical trial on pediatric relapsed acute leukemia.
The Pediatric Acute Leukemia (pedAL) trial will occur at 200 sites in the U.S., Australia, Canada and New Zealand that are part of the Children’s Oncology Group network of children’s hospitals and will test a variety of novel treatments simultaneously. PRA will provide trial management and oversight.
PedAL’s goal is to establish a genetic sequencing process to identify patterns and drivers of the disease, consolidate pediatric cancer data from multiple institutions into a single data set that will be available to researchers worldwide and form a global collaborative to standardize pediatric leukemia drug development efforts.